Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Co.'s focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ß. Co.'s main product candidate, PLN-74809, is a dual selective inhibitor of avß6 and avß1 integrins that Co. is developing for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Co.'s second product candidate, PLN-1474, is a selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which Co. has partnered with Novartis Institutes for Biomedical Research, Inc. We show 16 historical shares outstanding datapoints in our PLRX shares outstanding history coverage, used to compute PLRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PLRX market cap history over the course of time is important for investors
interested in comparing PLRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PLRX versus a peer is one thing; comparing
PLRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PLRX can fluctuate over the course of history.
With this page we aim to empower investors researching PLRX by allowing them to research the PLRX market cap history. |
Free PLRX Email Alerts:
Video: The Importance of Market Cap
